Cytokine Release Syndrome: Current Perspectives

Cytokine Release Syndrome: Current Perspectives

Hemant Murthy,1 Madiha Iqbal,1 Julio C Chavez,2 Mohamed A Kharfan-Dabaja1 1Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA; 2Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USACorrespondence: Mohamed A Kharfan-Dab...

Full description

Bibliographic Details
Main Authors:	Murthy H, Iqbal M, Chavez JC, Kharfan-Dabaja MA
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-10-01
Series:	ImmunoTargets and Therapy
Subjects:	cytokine release syndrome chimeric antigen receptor t-cell therapy
Online Access:	https://www.dovepress.com/cytokine-release-syndrome-current-perspectives-peer-reviewed-article-ITT

Similar Items

Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date
by: Si S, et al.
Published: (2020-08-01)

Cervical Edema Extending to the Larynx as Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-Cell Therapy in a Boy with Refractory Acute Lymphoblastic Leukemia
by: Haruko Shima, et al.
Published: (2022-03-01)

Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome
by: Hanfei Guo, et al.
Published: (2022-03-01)

Cytokine Release Syndrome: An Overview on its Features and Management
by: Shailza Shreshtha, et al.
Published: (2019-03-01)

Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias
by: Cesar Clavijo Simbaqueba, et al.
Published: (2020-08-01)

Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy
by: Shuyi Ding, et al.
Published: (2023-11-01)

Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies
by: Linqin Wang, et al.
Published: (2024-03-01)

Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome
by: Na Zheng, et al.
Published: (2024-01-01)

Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment
by: Zhiling Yan, et al.
Published: (2021-02-01)

Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy
by: Lina Zhang, et al.
Published: (2021-02-01)

Macrophage, the potential key mediator in CAR-T related CRS
by: Zhaonian Hao, et al.
Published: (2020-07-01)

Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma
by: Xue Wang, et al.
Published: (2022-04-01)

IL-6/IFN-γ double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro
by: Huihui Zhang, et al.
Published: (2022-01-01)

Glycyrrhizin for treatment of CRS caused by CAR T-cell therapy: A pharmacological perspective
by: Xingxing Qi, et al.
Published: (2023-02-01)

Editorial: Understanding the Cytokine Release Syndrome: Toward Improving Cancer Immunotherapy
by: Beatriz Martín-Antonio
Published: (2021-03-01)

Administration of granulocyte-macrophage colony-stimulating factor enhanced chimeric antigen receptor T-cell expansion and cellular immunity recovery without inducing cytokine release syndrome
by: Ying Jiang, et al.
Published: (2022-11-01)

Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
by: Yongxian Hu, et al.
Published: (2016-08-01)

Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors
by: Gabrielle Leclercq, et al.
Published: (2022-12-01)

Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy
by: Hui Luo, et al.
Published: (2019-10-01)

CAR-T Therapy, the End of a Chapter or the Beginning of a New One?
by: Yasser Mostafa Kamel
Published: (2021-02-01)

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
by: Jin Zhou, et al.
Published: (2022-09-01)

Cytokine Release Syndrome in the Immunotherapy of Hematological Malignancies: The Biology behind and Possible Clinical Consequences
by: Tor Henrik Anderson Tvedt, et al.
Published: (2021-11-01)

Improved efficacy with early tocilizumab in the prophylaxis and treatment of cytokine release syndrome of chimeric antigen receptor T cell (CAR-T) therapy for diffuse large B-cell lymphoma than acute lymphoblastic leukemia
by: Chengxin Luan, et al.
Published: (2023-09-01)

Cytokine release syndrome
by: Alexander Shimabukuro-Vornhagen, et al.
Published: (2018-06-01)

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
by: Zhenguang Wang, et al.
Published: (2018-01-01)

Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment
by: Antonio Nenna, et al.
Published: (2022-07-01)

Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T‐cell therapy recipients
by: Marissa Z. Powell, et al.
Published: (2023-04-01)

Improving cell reinfusion to enhance the efficacy of chimeric antigen receptor T-cell therapy and alleviate complications
by: Zhihao Han, et al.
Published: (2024-04-01)

Case Report: Chimeric Antigen Receptor T Cells Induced Late Severe Cytokine Release Syndrome
by: Jinping He, et al.
Published: (2022-06-01)

CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives
by: Semira Sheikh, et al.
Published: (2022-08-01)

Double systemic cytokine release syndrome following sequential infusion of anti-CD22 and anti-CD19 chimeric antigen receptor T cells after autologous hematopoietic stem cell transplantation for a central diffuse large B-cell lymphoma patient: A case report and literature review
by: Jing Zheng, et al.
Published: (2023-01-01)

Reducing Hinge Flexibility of CAR-T Cells Prolongs Survival In Vivo With Low Cytokines Release
by: Ang Zhang, et al.
Published: (2021-10-01)

Control effect of Dasatinib on the treatment of acute myeloid leukemia and adverse events of CD123 targeting CAR-T: a case report and literature review
by: LI Chunmin, et al.
Published: (2024-02-01)

CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
by: Luis Gerardo Rodríguez-Lobato, et al.
Published: (2020-07-01)

Complications after CD19+ CAR T-Cell Therapy
by: Olaf Penack, et al.
Published: (2020-11-01)

Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors
by: Paris Kosti, et al.
Published: (2021-04-01)

Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy
by: Wen-Jie Gong, et al.
Published: (2022-08-01)

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
by: David Porter, et al.
Published: (2018-03-01)

Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies
by: Elizabeth L. Siegler, et al.
Published: (2020-08-01)

Extracorporeal cytokine removal in chimeric antigen receptor T-cell therapy associated cytokine release syndrome in patient with acute lymphoblastic leukemia. Case report
by: Antonina E. Shchekina, et al.
Published: (2021-07-01)